Immunodetection of human topoisomerase I-DNA covalent complexes.
Nucleic Acids Res
; 44(6): 2816-26, 2016 Apr 07.
Article
en En
| MEDLINE
| ID: mdl-26917015
ABSTRACT
A number of established and investigational anticancer drugs slow the religation step of DNA topoisomerase I (topo I). These agents induce cytotoxicity by stabilizing topo I-DNA covalent complexes, which in turn interact with advancing replication forks or transcription complexes to generate lethal lesions. Despite the importance of topo I-DNA covalent complexes, it has been difficult to detect these lesions within intact cells and tumors. Here, we report development of a monoclonal antibody that specifically recognizes covalent topo I-DNA complexes, but not free topo I or DNA, by immunoblotting, immunofluorescence or flow cytometry. Utilizing this antibody, we demonstrate readily detectable topo I-DNA covalent complexes after treatment with camptothecins, indenoisoquinolines and cisplatin but not nucleoside analogues. Topotecan-induced topo I-DNA complexes peak at 15-30 min after drug addition and then decrease, whereas indotecan-induced complexes persist for at least 4 h. Interestingly, simultaneous staining for covalent topo I-DNA complexes, phospho-H2AX and Rad51 suggests that topotecan-induced DNA double-strand breaks occur at sites distinct from stabilized topo I-DNA covalent complexes. These studies not only provide new insight into the action of topo I-directed agents, but also illustrate a strategy that can be applied to study additional topoisomerases and their inhibitors in vitro and in vivo.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
ADN
/
Regulación Neoplásica de la Expresión Génica
/
ADN-Topoisomerasas de Tipo I
/
Inhibidores de Topoisomerasa I
/
Anticuerpos Monoclonales
/
Antineoplásicos Fitogénicos
Límite:
Animals
/
Humans
Idioma:
En
Año:
2016
Tipo del documento:
Article